Literature DB >> 18196537

Histopathological and immunohistochemical characterization of canine prostate cancer.

Chen-Li Lai1, René van den Ham, Geert van Leenders, Jaco van der Lugt, Jan A Mol, Erik Teske.   

Abstract

BACKGROUND: In this study we try to identify the origin of canine prostate cancer (cPC) by classifying the tumors histological subtypes and relate these subtypes to their combined expressional characteristics of several tissue specific and differentiation markers.
METHODS: cPCs were examined histomorphologically and by immunohistochemical detection of the cytokeratin markers CK14, HMWCK, CK5, CK18, and CK7, and of the markers UPIII, PSA and PSMA.
RESULTS: Histopathologically, six growth patterns could be differentiated. The most frequent patterns were solid, cribriform and micropapillary growth patterns, while sarcomatoid, small acinar/ductal, and tubulo-papillary growth patterns were less frequent present. Solid growth patterns were significantly (P = 0.027) more often seen in castrated dogs. Immunohistochemically, about half of the cPC cases showed expression of PSA (8/20) and PSMA (10/20); 85% and 60% of the cPC expressed UPIII (17/20) and CK7 (12/20), while 13 and 12 cPC expressed CK5 and CK14, respectively; all cPC expressed CK18. CK14 was significantly more often and UPIII less frequent expressed in the solid growth patterns than in the micropapillary and cribriform patterns, respectively.
CONCLUSIONS: Canine prostate cancer appear to be more aggressive and of a less differentiated type than most common human prostate cancers. Comparing the expression patterns of the markers in cPC to those in normal canine prostate tissue, cPC most likely originates from the collecting ducts rather than from the peripheral acini. Given also the fact that canine prostate cancer is unresponsive to androgen withdrawal therapy, canine prostate cancer mostly resembles human, androgen refractory, poorly differentiated prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196537     DOI: 10.1002/pros.20720

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  25 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.

Authors:  Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman
Journal:  Prostate       Date:  2014-01-21       Impact factor: 4.104

Review 3.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

4.  Development of a brain metastatic canine prostate cancer cell line.

Authors:  Nanda K Thudi; Sherry T Shu; Chelsea K Martin; Lisa G Lanigan; Murali V P Nadella; Adrie Van Bokhoven; Jillian L Werbeck; Jessica K Simmons; Sridhar Murahari; William C Kisseberth; Matthew Breen; Christina Williams; Ching-Shih Chen; Laurie K McCauley; Evan T Keller; Thomas J Rosol
Journal:  Prostate       Date:  2011-02-14       Impact factor: 4.104

5.  Establishment and Characterization of FusionRed Stable Transfected Canine Prostate Adenocarcinoma and Transitional Cell Carcinoma Cells.

Authors:  Suhayla Alnajjar; Ingo Nolte; Jan Torben Schille; Sina Sender; Nares Trakoolju; Simon Villa Perez; Dietmar Zechner; Brigitte Vollmar; Christian Junghanss; Hugo Murua Escobar
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 6.  A Review on Canine and Feline Prostate Pathology.

Authors:  Chiara Palmieri; Carlos Eduardo Fonseca-Alves; Renee Laufer-Amorim
Journal:  Front Vet Sci       Date:  2022-05-26

7.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

Review 8.  Beyond tradition and convention: benefits of non-traditional model organisms in cancer research.

Authors:  Rebecca M Harman; Sanjna P Das; Arianna P Bartlett; Gat Rauner; Leanne R Donahue; Gerlinde R Van de Walle
Journal:  Cancer Metastasis Rev       Date:  2020-10-28       Impact factor: 9.264

9.  Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.

Authors:  R Sánchez-Céspedes; M D Fernández-Martínez; A I Raya; C Pineda; I López; Y Millán
Journal:  BMC Vet Res       Date:  2021-05-25       Impact factor: 2.741

10.  Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.

Authors:  Simone de Brot; Jennifer Lothion-Roy; Llorenç Grau-Roma; Emily White; Franco Guscetti; Mark A Rubin; Nigel P Mongan
Journal:  Vet Comp Oncol       Date:  2021-05-18       Impact factor: 2.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.